BioCentury | Feb 22, 2016
Clinical News
Toctino alitretinoin: Development discontinued
...GSK discontinued its Toctino U.S. program. Basilea, which granted GSK exclusive, worldwide rights to alitretinoin in...
...Pharmaceutica AG (SIX:BSLN), Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Toctino alitretinoin ( BAL4079...
...Pharmaceutica AG (SIX:BSLN), Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Toctino alitretinoin ( BAL4079...